Is there a cure for current weakness in Chinese health care stocks?

Capital Group
By December 6, 2022 10:00

Is there a cure for current weakness in Chinese health care stocks?

Health care has been the worst-returning sector in China since the peak of the market last year. Behind this decline has been geopolitical tensions, macroeconomic risks and domestic policy.

Long term, the outlook is still encouraging, however, with demographics supporting rising demand and healthcare spending, and domestic reform strengthening the sector’s fundamentals.

Selectivity is critical as the industry is nascent and, long term, there could only be a handful of winners. Those likely to benefit are companies with China-originated innovations, differentiated therapies, and partnerships with multinational pharmaceutical companies they can use to expand beyond the local market.

Asset Manager

Capital Group is one of the largest and most experienced investment management companies in the world

Capital Group is in 1931 opgericht in de Verenigde Staten en een van de grootste onafhankelijke vermogensbeheerders ter wereld met een actief beheerd vermogen van meer dan $2,1 biljoen. We doen alleen vermogensbeheer. Al 90 jaar is het ons primaire doel om een consistent en superieur resultaat te realiseren voor langetermijnbeleggers.

Website:capitalgroup.com

Feike Goudsmit
Managing Director, Institutional
Tel: +31 (0) 20 797 7575
E-mail: feike.goudsmit@capitalgroup.com

LinkedIn: capital-group-europe

Capital Group
By December 6, 2022 10:00

SEARCH